NeXT Level
Biomarkers Symposium

NeXT Level Biomarkers Symposium

The 2021 Personalis NeXT Level Biomarkers Symposium showcased the latest research from Personalis’ ImmunoID NeXT Platform™ and highlighted key applications of the most comprehensive immunogenomics solution for translational research. The Personalis Research and Development team presented the latest insights and applications from our internal research and highlighted the technical capabilities of ImmunoID NeXT. A presentation from one of our collaboration partners, the Parker Institute for Cancer Immunotherapy, also demonstrated how the ImmunoID NeXT Platform is impacting real world biomarker discovery in clinical trials.

Agenda

The 2021 NeXT Level Biomarkers Symposium covered novel research put forth by the Personalis R&D team as well as a client presentation from our partners at the Parker Institute for Cancer Immunotherapy. Topics included:

  • HLA LOH and HLA typing using our Deletion of Allele-Specific HLAs (DASH) technology
  • Neoantigen prediction capabilities using our Systematic HLA Epitope Ranking Pan Algorithm (SHERPA)
  • NeXT Dx and companion diagnostics development from NGS data
  • Case study on leveraging the data from Personalis’ ImmunoID NeXT Platform from the Parker Institute for Cancer Immunotherapy

Welcome Message

Richard Chen, MD, MS

Chief Scientific Officer
Personalis, Inc.

Presentations

Biomarker Discovery with ImmunoID NeXT Platform

Erin Newburn, PhD

Erin Newburn, MS, PhD

Director, Field Applications Scientist
Personalis, Inc. 

View Presentation

Exploring HLA LOH With the DASH (Deletion of Allele-Specific HLAs) Algorithm

Rachel Pyke, PhD

Manager, Bioinformatics Applications
Personalis, Inc. 

View Presentation

Neoantigen Binding Prediction and Biomarker Discovery with SHERPA

Sean Boyle, PhD

Senior Director, Bioinformatics Applications
Personalis, Inc.

View Presentation

Composite Biomarkers and our Neoantigen Presentation Score (NEOPS)

Charles Abbott

Charles Abbott, PhD

Manager Bioinformatics Science
Personalis, Inc.

View Presentation

Parker Institute Case Study: The PRINCE Trial

Theresa LaVallee, PhD

Vice President, Translation Medicine and Regulatory Affairs
Parker Institute for Cancer Immunotherapy

Lee McDaniel

Lee McDaniel, MD, MSE

Sr. Bioinformatics Scientist
Personalis, Inc. 

NeXT Liquid Biopsy Overview and Review of AACR Data

Dan Norton

Dan Norton, MBA

Senior Product Manager
Personalis, Inc.

Sean Boyle, PhD

Senior Director, Bioinformatics Applications
Personalis, Inc.

NeXT Dx and Companion Diagnostics (CDx) with Personalis

Twinkal Marfatia

Twinkal Marfatia, PhD

Sr. Product Manager – Clinical Products
Personalis, Inc.

Dawn McHugh

Sr. Director, Strategic Business Development
Personalis, Inc.